Beijing GoBroad Hospital
China's pioneering research hospital for complex cancers β leading the world in CAR-T cell therapy, hematologic malignancies, and early-phase clinical trials for patients who have run out of standard options.
About Beijing GoBroad Hospital
Beijing GoBroad Hospital is China's first international research-oriented hospital, located in the ZhongGuanCun Life Science Park in Changping District, Beijing. Built on a 100,000-square-metre campus with eight above-ground and three underground floors, the hospital was developed by GoBroad Healthcare Group β a network founded in 2017 and backed by Hillhouse Capital β and officially opened in 2023. The Group now operates eight hospitals across Beijing, Shanghai and Guangzhou with a combined capacity approaching 1,500 beds.
The hospital's cancer programme is built around four core business sectors: the Centre for Challenging and Critical Care Medicine, the Clinical Research Centre, the Precision Diagnostics Centre, and the Data Intelligence Centre. It specialises in solid tumours, hematologic malignancies and brain science, with particular strength in CAR-T cell immunotherapy, haematopoietic stem cell transplantation (HSCT), Lu-177 radionuclide therapy, and early-phase drug trials. The hospital holds a registered Clinical Trial Institution for drug and medical device studies and operates four dedicated radionuclide treatment wards capable of treating up to 200 patients per year. Over half of the clinical team is dedicated to research and clinical innovation.
GoBroad Healthcare Group was formally admitted to the European Society for Blood and Marrow Transplantation (EBMT) in 2025, confirming its compliance with internationally recognised transplant and research standards. GoBroad-affiliated haematology programmes have been ranked among China's Top 30 haematopoietic stem cell transplant centres for three consecutive years. The hospital's Ethics Review Committee upholds international GCP standards for all clinical research, and the AECOM-designed facility integrates global hospital design principles with the demands of dual research-and-care operations.
CancerFax works directly with Beijing GoBroad Hospital's International Patient Service Centre to help patients worldwide access its specialist oncology programmes. From submitting medical records and securing a clinical review to coordinating visa support and pre-arrival briefings, CancerFax manages the entire process at no cost to the patient β ensuring that those who need GoBroad's most innovative therapies can reach them without logistical barriers.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Beijing (Changping District) |
| Established | 2017 (group); opened 2023 (main campus) |
| Hospital Type | International Research Hospital β Tertiary Oncology |
| Accreditation | EBMT Member Β· GCP-Compliant Clinical Trial Institution Β· Beijing ICP Licensed |
| Beds | 500 planned (100 dedicated early-stage research beds) |
| Annual Cancer Patients | β VERIFY: 3,000+ |
| Research Focus | CAR-T cell therapy, HSCT, solid tumours, hematologic malignancies, Lu-177 radionuclide therapy, Phase IβIII drug trials |
Why Patients Choose Beijing GoBroad Hospital
Beijing GoBroad Hospital is built for patients with complex, refractory, or relapsed cancers who need access to therapies not yet available elsewhere. Its ARO model uniquely combines elite clinical expertise with early-phase trial infrastructure under one roof.
Cancer Specialties and Clinical Departments
Beijing GoBroad Hospital focuses on the most complex oncology presentations, with dedicated disease-specific teams for blood cancers, solid tumours and rare malignancies supported by an integrated research infrastructure.
Advanced Treatment Capabilities
Key Specialists at Beijing GoBroad Hospital
Beijing GoBroad Hospital has assembled a multidisciplinary team of nationally and internationally recognised clinical experts, with more than half of all medical and research staff dedicated to clinical innovation and translational medicine. The hospital operates a full MDT structure for cancer care, drawing together haematologists, oncologists, transplant specialists, molecular biologists, pathologists, nuclear medicine physicians and radiologists for every complex case. The Clinical Trial Institution alone is supported by seven nationally renowned lead investigators.
Senior oncologists include Dr. Xiaoyan Ke (haematology), Professor Lu Ming (nuclear medicine and gastroenterology), Dr. Shen Lin (medical oncology), Dr. Chunrong Tong (cellular immunotherapy), Dr. Li Jin (gastrointestinal oncology and clinical trials) and Dr. Changsong Qi (oncology and CAR-T research). Many hold concurrent appointments at premier institutions including Peking Union Medical College Hospital. Patients seeking a consultation with a specific physician or a multidisciplinary second opinion may submit their request through the CancerFax coordination process before confirming travel.
Patients seeking specific physician consultations or second opinions may request a review through the CancerFax coordination process before confirming travel or admission.
Clinical Infrastructure and Treatment Technology
Beijing GoBroad Hospital's 100,000-square-metre campus integrates hospital-grade clinical care with research-grade infrastructure β including dedicated Phase I trial wards, a central laboratory, imaging core, pathology core and four nuclear medicine treatment wards β across eight above-ground floors designed by AECOM to international hospital standards.
- Varian TrueBeam linear accelerator for precision external beam radiotherapy
- Lu-177 radionuclide therapy β 4 dedicated wards, up to 200 patients/year (PRRT)
- β VERIFY: Proton therapy system (reported; confirm direct with GoBroad International Desk)
- 3T MRI for high-resolution tumour characterisation
- PET/CT scanners for metabolic staging and treatment response
- Dedicated Imaging Core integrated with Clinical Research Centre
- Robot-assisted minimally invasive surgical systems for solid tumour resection
- Apheresis and CAR-T cell manufacturing pipeline with HSCT-capable transplant wards
- Interventional oncology suite for image-guided tumour ablation procedures
- Next-generation sequencing (NGS) and liquid biopsy for molecular tumour profiling
- Registered Phase IβIII Clinical Trial Institution with GCP-compliant investigational drug management
- Cardiac Safety Assessment Centre and Clinical Pharmacology unit for early-phase oncology drug trials
International Patient Support at Beijing GoBroad Hospital
Beijing GoBroad Hospital operates a dedicated International Patient Service Centre providing end-to-end support for patients travelling from outside China β covering pre-arrival medical review, appointment coordination, visa facilitation, and in-hospital language assistance.
What to Prepare Before Traveling
- arrow_rightShare all pathology reports, biopsy slides, imaging (CT/PET/MRI) and prior treatment summaries in English at least one week before your appointment β the GoBroad team will review eligibility for CAR-T, HSCT, or clinical trial enrolment in advance.
- arrow_rightObtain a Medical Visa (S2) for China; the International Patient Service Centre can provide an official hospital invitation letter to support your application at the Chinese embassy in your country.
- arrow_rightArrange travel to Beijing and confirm ground transport to Building 1, No. 4 Science Park Road, Changping β the hospital is accessible via the Changping Metro Line (Life Science Park Station, east exit) plus a short bus or taxi connection.
To contact Beijing GoBroad Hospital's International Patient Service Centre directly, call +86 400-696-2000 (MondayβFriday, 08:30β17:30 CST) or reach out via the GoBroad Healthcare website at gobroadhealthcare.com/En. CancerFax coordinates all communication with the international desk on your behalf β submit your reports to us and we will manage the referral at no cost.
Patient Facilities and Accommodation at Beijing GoBroad Hospital
The hospital's AECOM-designed 100,000-square-metre campus was purpose-built to integrate comfortable patient care with active clinical research, offering modern inpatient facilities across eight above-ground floors in Beijing's Changping Life Science Park.
Family members accompanying international patients are advised to book accommodation near the Life Science Park Metro Station (Changping Line); the International Patient Service Centre can recommend nearby hotels and assist with shuttle arrangements to the hospital campus.
How to Reach Beijing GoBroad Hospital
Beijing GoBroad Hospital is located in the ZhongGuanCun Life Science Park in Changping District, approximately 30 kilometres north-west of central Beijing β accessible from both major international airports and by metro.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Beijing GoBroad Hospital β Patient Questions Answered
CancerFax acts as your personal coordinator throughout the entire process. You begin by uploading your medical records β pathology, imaging, prior treatment history β through our secure platform. Our clinical team reviews your case and assesses whether GoBroad's specialist programmes (CAR-T, HSCT, clinical trials, Lu-177 therapy or MDT review) are relevant for your diagnosis. We then submit your case directly to GoBroad's International Patient Service Centre and work with their team to arrange the right department, the right specialist, and the right appointment.
Once your consultation is confirmed, CancerFax prepares a full pre-travel briefing covering expected costs, visa documentation requirements, transport to the Changping campus, and what to bring on the day. We remain your single point of contact from first enquiry through to consultation completion. CancerFax charges patients nothing for this service β our goal is to remove every barrier between you and the treatment you need.
Beijing GoBroad Hospital's deepest expertise lies in haematologic malignancies β including relapsed or refractory leukaemia, lymphoma, multiple myeloma and myelodysplastic syndromes β where it is among China's most experienced centres for CAR-T cell therapy and haematopoietic stem cell transplantation. Beyond blood cancers, the hospital has strong programmes for solid tumours including lung, gastric, liver and pancreatic cancers, and a dedicated neurosciences unit for brain tumours. It also leads one of the few Lu-177 radionuclide therapy programmes in China, relevant for neuroendocrine tumours. If you are unsure whether your diagnosis falls within GoBroad's scope, submit your records through CancerFax and we will confirm eligibility before you make any travel plans.
Yes β CAR-T cell immunotherapy is one of GoBroad's flagship programmes. GoBroad-affiliated facilities have performed over 4,000 CAR-T infusions to date, with particular expertise in dual-target constructs (CD19+CD22) for relapsed or refractory B-cell leukaemia and lymphoma, and BCMA-targeting therapies for multiple myeloma. The hospital also has active CAR-T protocols for solid tumours, including trials targeting Claudin18.2 in gastric cancer. International patients do receive CAR-T treatment here β GoBroad's International Patient Service Centre provides English-speaking coordinators, visa invitation letters and in-hospital translation throughout the process. CancerFax can assess your eligibility and submit your records to the CAR-T team before you travel.
Yes. Beijing GoBroad Hospital can review medical records and provide a specialist opinion remotely before a patient commits to travel. The process typically involves submitting scans, pathology reports and treatment history β ideally in English β to the International Patient Service Centre. CancerFax facilitates this submission and follows up with the clinical team on your behalf to obtain a written opinion or preliminary treatment recommendation, usually within one to two weeks depending on case complexity. This remote review is particularly useful for patients considering enrolment in a clinical trial or assessing eligibility for CAR-T or Lu-177 therapy before arranging travel.
Consultation fees at Beijing GoBroad Hospital are generally more affordable than comparable specialist centres in North America, Europe or the Gulf β though exact costs vary by specialist seniority, department and whether diagnostic tests are required on the day. For complex cases involving CAR-T eligibility assessment or clinical trial screening, additional diagnostic fees (NGS, liquid biopsy, imaging) are typically quoted separately. CancerFax requests an itemised cost estimate from GoBroad's International Patient Service Centre as part of the pre-travel package β this is provided to you at no extra charge before you confirm your appointment. We do not add any mark-up to hospital fees. If you have international health insurance, we can also advise on documentation requirements for reimbursement claims.
Send Your Medical Reports to Beijing GoBroad Hospital via CancerFax
CancerFax reviews your records and coordinates your consultation at Beijing GoBroad Hospital β China's leading research hospital for complex cancers. No cost, no obligation, and complete confidentiality throughout.